期刊
BLOOD
卷 139, 期 7, 页码 983-994出版社
AMER SOC HEMATOLOGY
DOI: 10.1182/blood.2020005466
关键词
-
类别
资金
- National Heart, Lung and Blood Institute, National Institutes of Health (NIH) [T32 HL110841]
- Mark Foundation for Cancer Research
- National Cancer Institute, NIH [2P01 CA148600, P01 CA225618]
- Board of Visitors of the Children's National Health System
Epstein-Barr virus (EBV) is a common human tumor virus associated with lymphoproliferative diseases. The presence of EBV provides a unique target for therapies targeting EBV.
Epstein-Barr virus (EBV) is a ubiquitous human tumor virus, which contributes to the development of lymphoproliferative disease, most notably in patients with impaired immunity. EBV-associated lymphoproliferation is characterized by expression of latent EBV proteins and ranges in severity from a relatively benign proliferative response to aggressive malignant lymphomas. The presence of EBV can also serve as a unique target for directed therapies for the treatment of EBV lymphoproliferative diseases, including T cell-based immune therapies. In this review, we describe the EBV-associated lymphoproliferative diseases and particularly focus on the thera-pies that target EBV.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据